Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 688 results
Found 688 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

F

Ferreira MAR, Mangino M, Brumme CJ, et al. "Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control." Am. J. Hum. Genet.. 2010;86(1):88-92.
Fichtenbaum CJ, Yeh T-min, Evans SR, Aberg JA. "Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087." J Clin Lipidol. 2010;4(4):279-87.
Fichtenbaum CJ, Evans SE, Aberg JA. "High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection." AIDS. 2011;25(16):2053.
Fife KH, Wu JW, Squires KE, D Watts H, Andersen JW, Brown DR. "Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2009;51(3):274-82.
Firnhaber C, Smeaton L, Saukila N, et al. "Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas." Int. J. Infect. Dis.. 2010;14(12):e1088-92.
Firnhaber C, Smeaton LM, Grinsztejn B, et al. "Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial." HIV Clin Trials. 2015;16(3):89-99.
Fischl MA, Collier AC, A Mukherjee L, et al. "Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen." AIDS. 2007;21(3):325-33.
Fiscus SA, Cu-Uvin S, Eshete ATilahun, et al. "Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy." Clin. Infect. Dis.. 2013;57(2):290-7.
Flexner C. "HIV drug development: the next 25 years." Nat Rev Drug Discov. 2007;6(12):959-66.
Flexner C, Tierney C, Gross R, et al. "Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial." Clin. Infect. Dis.. 2010;50(7):1041-52.
Foulkes AS, DeGruttola VG. "A resampling-based approach to multiple testing with uncertainty in phase." Int J Biostat. 2007;3(1):Article 2.
Foulkes AS, Wohl DA, Frank I, et al. "Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy." PLoS Med.. 2006;3(3):e52.
Freeman ML, Lederman MM, Gianella S. "Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection." Curr HIV/AIDS Rep. 2016;13(1):10-9.
Freeman ML, Shive CL, Nguyen TP, Younes S-A, Panigrahi S, Lederman MM. "Cytokines and T-Cell Homeostasis in HIV Infection." J. Infect. Dis.. 2016;214 Suppl 2:S51-7.
Funderburg N, Lederman MM, Feng Z, et al. "Human -defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2." Proc. Natl. Acad. Sci. U.S.A.. 2007;104(47):18631-5.
Funderburg NT, Xu D, Playford MP, et al. "Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity." Antivir. Ther. (Lond.). 2017;22(1):71-75.
Funderburg NT, Andrade A, Chan ES, et al. "Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine." PLoS ONE. 2013;8(12):e83514.
Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, Lederman MM. "Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis." PLoS ONE. 2008;3(4):e1915.

G

Gallien S, Delaugerre C, Charreau I, et al. "Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia." AIDS. 2011;25(5):665-9.
Gandhi RT, Coombs RW, Chan ES, et al. "No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2012;59(3):229-35.
Gandhi RT, O'Neill D, Bosch RJ, et al. "A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy." Vaccine. 2009;27(43):6088-94.
Gandhi RT, Bosch RJ, Aga E, et al. "No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy." J. Infect. Dis.. 2010;201(2):293-6.
Gandhi RT, McMahon DK, Bosch RJ, et al. "Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation." PLoS Pathog.. 2017;13(4):e1006285.
Gandhi RT, Bosch RJ, Aga E, et al. "Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173." Antivir. Ther. (Lond.). 2013;18(4):607-13.
Gandhi RT, Zheng L, Bosch RJ, et al. "The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial." PLoS Med.. 2010;7(8).

Pages